{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:24:37Z","timestamp":1787761477625,"version":"build-2784847793"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A remarkable new American Heart Association calculator for estimating risk of cardiovascular disease was released in 2024, with guidelines following in 2026. These guidelines now use non\u2013high-density lipoprotein cholesterol (HDL-C) along with low-density lipoprotein cholesterol to guide and escalate therapy. Moreover, the calculator uses non\u2013HDL-C as the primary screening lipoprotein marker to fully capture the hidden cholesterol burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For its Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator, the American Heart Association compiled an immense, diverse dataset comprising more than 6.5 million US adults. The PREVENT equations not only use the conventional nonlipid risk markers but also reframe how cardiovascular disease is assessed by embedding it into a cardiovascular-kidney-metabolic syndrome framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Why did PREVENT not use apolipoprotein B (apo B) for the primary marker? In head-to-head comparisons, apo B has consistently been shown to outperform non\u2013HDL-C, especially in high-risk syndromes. Here, using receiver operating characteristic curve analysis and C statistics, I show that after adjustment for conventional risk factors, apo B and non\u2013HDL-C are equivalent for screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The guidelines suggest that apo B be used for risk reclassification and as needed for targeting of statin and ezetimibe therapy. Here, I clarify the reasons for this suggestion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmag054","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:22:08Z","timestamp":1786706528000},"source":"Crossref","is-referenced-by-count":0,"title":["Review of the American Heart Association PREVENT guidelines: how non\u2013high-density lipoprotein cholesterol and apolipoprotein B fit in"],"prefix":"10.1093","volume":"57","author":[{"given":"Stanley S","family":"Levinson","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Endocrinology, Metabolism & Diabetes, University of Louisville , Louisville, KY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082611503648500_lmag054-B1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/labmed\/lmz032","article-title":"Non-high-density lipoprotein cholesterol and guidelines for cholesterol lowering in recent history","volume":"51","author":"Levinson","year":"2020","journal-title":"Lab Med"},{"key":"2026082611503648500_lmag054-B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"148","author":"The expert panel","year":"1988","journal-title":"Arch Intern Med"},{"key":"2026082611503648500_lmag054-B4","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/CIRCULATIONAHA.126.079538","article-title":"The 2026 American College of Cardiology\/American Heart Association Multisociety Guideline on the Management of Dyslipidemia: a more precise\u2014but more complicated\u2014framework for atherosclerotic cardiovascular disease prevention and treatment","volume":"153","author":"Watson","year":"2026","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B6","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001423","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"153","author":"Writing Committee","year":"2026","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/aa.111819","article-title":"What\u2019s new in the AHA\/ACC 2026 guidelines for the management of dyslipidemia","volume":"32","author":"Che\u0142stowska","year":"2026","journal-title":"Acta Angiologica"},{"key":"2026082611503648500_lmag054-B8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/s-2004-835379","article-title":"Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis","volume":"4","author":"Aguilar Salinas","year":"2004","journal-title":"Semin Vasc Med"},{"key":"2026082611503648500_lmag054-B9","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1001\/jama.1988.03410130125037","article-title":"Low-density lipoprotein subclass patterns and risk of myocardial infarction","volume":"260","author":"Austin","year":"1988","journal-title":"JAMA"},{"key":"2026082611503648500_lmag054-B10","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1161\/01.cir.101.24.2777","article-title":"Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study","volume":"101","author":"Austin","year":"2000","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B11","doi-asserted-by":"publisher","first-page":"13B","DOI":"10.1016\/s0002-9149(98)00032-0","article-title":"Atherogenicity of triglyceride-rich lipoproteins","volume":"81","author":"Krauss","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026082611503648500_lmag054-B12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MOL.0000000000000824","article-title":"Small dense low-density lipoprotein particles: clinically relevant?","volume":"33","author":"Krauss","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"2026082611503648500_lmag054-B13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2026082611503648500_lmag054-B15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988: role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"2026082611503648500_lmag054-B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0009-8981(93)90060-h","article-title":"Immunonephelometric\/turbidimetric apolipoprotein B assays for the clinical laboratory","volume":"223","author":"Levinson","year":"1993","journal-title":"Clin Chim Acta"},{"key":"2026082611503648500_lmag054-B17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamacardio.2021.5080","article-title":"Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over","volume":"7","author":"Sniderman","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026082611503648500_lmag054-B18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/circoutcomes.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026082611503648500_lmag054-B19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1309\/22M22RF48PX9UT9T","article-title":"Comparison of apolipoprotein B and non-high-density lipoprotein cholesterol for identifying coronary artery disease risk based on receiver operating curve analysis","volume":"127","author":"Levinson","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"2026082611503648500_lmag054-B20","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1161\/01.CIR.0000145660.60487.94","article-title":"Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study","volume":"110","author":"Sattar","year":"2004","journal-title":"Circulation"},{"key":"2026082611503648500_lmag054-B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/jalm\/jfae125","article-title":"Non-HDL cholesterol may be preferred over Apolipoprotein B-100 for risk assessment when evaluated by receiver operator characteristic curve analysis","volume":"10","author":"Levinson","year":"2025","journal-title":"J Appl Lab Med"},{"key":"2026082611503648500_lmag054-B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"2026082611503648500_lmag054-B23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jamacardio.2026.0898","article-title":"Non-HDL cholesterol and apolipoprotein B measures and risk of atherosclerotic cardiovascular disease","volume":"11","author":"Johannesen","year":"2026","journal-title":"JAMA Cardiol"},{"key":"2026082611503648500_lmag054-B24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"J Lipid Res"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/57\/5\/lmag054\/70805700\/lmag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/57\/5\/lmag054\/70805700\/lmag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:50:43Z","timestamp":1787759443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/doi\/10.1093\/labmed\/lmag054\/8771087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmag054","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"lmag054"}}